Literature DB >> 15683666

HIV infection and invasive cervical cancers, treatment with radiation therapy: toxicity and outcome.

Shyam Kishore Shrivastava1, Reena Engineer, Sunil Rajadhyaksha, Ketayun A Dinshaw.   

Abstract

BACKGROUND AND
PURPOSE: To determine the effect of radiotherapy in HIV seropositive cervical cancer patients, tumour response and toxicity and compliance of patients to the treatment. PATIENTS AND METHODS: This study is a retrospective review of 42 HIV seropositive patients diagnosed with carcinoma cervix, between 1997 and 2003 at the Tata Memorial Hospital. The age and symptoms of presentation, clinical stage, response, compliance and tolerance to radiotherapy were studied.
RESULTS: Mean age at presentation was 41 years. All patients presented with the symptoms of cervical disease. Of these patients 31(74%) patients had 'Karnofsky Performance Scale' (KPS) more than 80%. Twenty-one (50%) of the patients were of Stage IIIb-IVa. Thirty-two (76%) were started on radiotherapy with radical intent. Compliance to radiotherapy was poor with 24% patients discontinuing after few fractions of radiotherapy. Seven (17%) patients were given palliative radiotherapy. Twenty-two patients completed prescribed radical radiotherapy and 50% of these achieved complete response. Grade III-IV acute gastrointestinal toxicity was seen in 14% of the patients, and grade III acute skin toxicity was seen in 27% of patients, leading to treatment delays. There was good relief of symptoms in patients treated with palliative intent.
CONCLUSIONS: Radiotherapy is effective in this set of patients. Palliative fractionation schedules are effective for patients with poor performance status and locally advanced cancers in relieving the symptoms related to carcinoma cervix. An emphasis should be given to the increased acute mucosal and skin toxicity and to improving compliance and clinical outcome of these patients.

Entities:  

Mesh:

Year:  2005        PMID: 15683666     DOI: 10.1016/j.radonc.2004.11.006

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa.

Authors:  Hannah M Simonds; Jason D Wright; Naomi du Toit; Alfred I Neugut; Judith S Jacobson
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

2.  HIV Status and Acute Hematologic Toxicity Among Patients With Cervix Cancer Undergoing Radical Chemoradiation.

Authors:  Hannah M Simonds; Alfred I Neugut; Judith S Jacobson
Journal:  Int J Gynecol Cancer       Date:  2015-06       Impact factor: 3.437

Review 3.  Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary?

Authors:  Nadine Housri; Robert Yarchoan; Aradhana Kaushal
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

4.  Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting.

Authors:  Surbhi Grover; Memory Bvochora-Nsingo; Alyssa Yeager; Sebathu Chiyapo; Rohini Bhatia; Emily MacDuffie; Priya Puri; Dawn Balang; Sarah Ratcliffe; Mohan Narasimhamurthy; Elliphine Gwangwava; Sylvia Tsietso; Mukendi K A Kayembe; Doreen Ramogola-Masire; Scott Dryden-Peterson; Umesh Mahantshetty; Akila N Viswanathan; Nicola M Zetola; Lilie L Lin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-02-01       Impact factor: 7.038

Review 5.  Optimal management of cervical cancer in HIV-positive patients: a systematic review.

Authors:  Atara Ntekim; Oladapo Campbell; Dietrich Rothenbacher
Journal:  Cancer Med       Date:  2015-07-01       Impact factor: 4.452

6.  The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.

Authors:  Jens Kübler; Stefanie Kirschner; Linda Hartmann; Grit Welzel; Maren Engelhardt; Carsten Herskind; Marlon R Veldwijk; Christian Schultz; Manuela Felix; Gerhard Glatting; Patrick Maier; Frederik Wenz; Marc A Brockmann; Frank A Giordano
Journal:  Oncotarget       Date:  2016-07-19

7.  Human immunodeficiency virus seroprevalence in patients with invasive cervical cancer in Zaria, North-Western Nigeria.

Authors:  Adamu Abdullahi; Muhammad Inuwa Mustapha; Dawotola Ayorinde David; Olasinde Tajudeen Ayodeji
Journal:  Ann Afr Med       Date:  2018 Jan-Mar

8.  Effect of COVID-19 Pandemic on Gynecological Cancer Radiation During Complete Nationwide Lockdown: Observations and Reflections From Tertiary Care Institute in India.

Authors:  Abhishek Shinghal; Sonz Paul; Supriya Chopra; Lavanya Gurram; Libin Scaria; Satish Kohle; Priyanka Rane; Dheera A; John Puravath; Jivanshu Jain; Jamema Swamidas; Jaya Ghosh; Sudeep Gupta; Sushmita Rath; Sarbani Ghosh Laskar; Jai Prakash Agarwal
Journal:  Adv Radiat Oncol       Date:  2021-05-28

9.  Outcomes of Cervical Cancer in HIV-Positive Women Treated With Radiotherapy at a Tertiary Care Center in India.

Authors:  Lavanya Gurram; Samarpita Mohanty; Supriya Chopra; Surbhi Grover; Reena Engineer; Sudeep Gupta; Jaya Ghosh; Seema Gulia; Sheela Sawant; Anuprita Daddi; Kedar Deodhar; Santosh Menon; Bharat Rekhi; T S Shylasree; Amita Maheshwari; Umesh Mahantshetty
Journal:  JCO Glob Oncol       Date:  2022-03

10.  Chromosomal radiosensitivity of human immunodeficiency virus positive/negative cervical cancer patients in South Africa.

Authors:  Olivia Herd; Flavia Francies; Jeffrey Kotzen; Trudy Smith; Zwide Nxumalo; Xanthene Muller; Jacobus Slabbert; Anne Vral; Ans Baeyens
Journal:  Mol Med Rep       Date:  2015-11-05       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.